2018
DOI: 10.1503/cmaj.170453
|View full text |Cite
|
Sign up to set email alerts
|

The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

4
97
1
3

Year Published

2018
2018
2024
2024

Publication Types

Select...
4
2

Relationship

1
5

Authors

Journals

citations
Cited by 103 publications
(111 citation statements)
references
References 83 publications
4
97
1
3
Order By: Relevance
“…Similar to previous reports, the GT3 SVR rate for SOF + RBV was sub‐optimal . Currently, newer DAA regimens such as sofosbuvir plus daclatasvir or velpatasvir‐based regimens or glecaprevir/pibrentasvir are the recommended GT3 therapies …”
Section: Discussionsupporting
confidence: 79%
See 4 more Smart Citations
“…Similar to previous reports, the GT3 SVR rate for SOF + RBV was sub‐optimal . Currently, newer DAA regimens such as sofosbuvir plus daclatasvir or velpatasvir‐based regimens or glecaprevir/pibrentasvir are the recommended GT3 therapies …”
Section: Discussionsupporting
confidence: 79%
“…[41][42][43] Currently, newer DAA regimens such as sofosbuvir plus daclatasvir or velpatasvir-based regimens or glecaprevir/ pibrentasvir are the recommended GT3 therapies. 33,40,41 Although, it has been shown that IDU and OST could significantly reduce the SVR, 44 in our study these factors were not associated with treatment effectiveness. In a recent study, it has been shown that reinfection rate is higher among recent IDU compared to past IDU.…”
Section: Yescontrasting
confidence: 68%
See 3 more Smart Citations